Metzgar R S, Mohanakumar T, Bolognesi D P
J Exp Med. 1976 Jan 1;143(1):47-63. doi: 10.1084/jem.143.1.47.
Leukemic cells from all human chronic granulocytic leukemia (CGL) and some acute myelomonocytic leukemia (AMML) donors are lysed by rabbit antisera to a purified glycoprotein of Friend murine leukemia virus (FLV gp71) in a microcytotoxicity assay. These antisera are not cytotoxic to cells from patients with acute myelocytic leukemia (AML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), or to peripheral blood lymphocytes from normal donors. A goat antiserum to gradient purified FLV in addition to reacting with cells from CGL and AMML donors also reacted with cells from AML patients and some ALL donors. However, this antiserum failed to react with cells from CLL patients. Peripheral blood and bone marrow leukocytes prepared from leukemic patients in clinical remission failed to react with antisera to FLV and FLV gp71. Absorption experiments demonstrated that the antigen on CGL cells which is reacting with the antiserum to FLV gp71 is also present on normal human platelets and neutrophils. Similar absorption studies showed that the antigen on AML cells detected by the FLV antiserum is not present on normal leukocytes and platelets and appears to be related to the major internal p30 antigens of mammalian RNA tumor viruses. Another antigenic relationship between oncornaviruses and membrane antigens of human leukemia cells was shown by the ability of FLV antigens to absorb the cytotoxic reactivity of nonhuman primate antisera detecting human leukemia-associated antigens. FLV and FLV gp71 antigens were able to absorb all cytotoxic activity of monkey and chimpanzee antisera to human myeloid leukemia antigens when these antisera were tested with CGL cells. These two approaches to an analysis of cross-reactivity indicate that the antigenic determinant(s) detected by the cytotoxic reactions of the FLV gp71 antiserum with human CGL cells is different from the determinant on FLV gp71 which is responsible for the inhibition of the reactivity of simian antisera with CGL cells. Since the goat and rabbit antisera to FLV and FLV gp71 are able to distinguish AML from CGL cells by direct cytotoxicity testing and absorption, they may be valuable reagents for the serological diagnosis of myeloid leukemia. In addition, since peripheral blood cells from AML and CGL patients in clinical remission were seronegative, the antisera may be valuable as management aids. The data in this report indicates that whatever the mechanism of leukemogenesis is in man, cells from CGL and AML patients possess certain membrane antigens which cross-react with FLV structural components such as p30 and gp71.
在微量细胞毒性试验中，兔抗Friend小鼠白血病病毒（FLV）纯化糖蛋白（FLV gp71）的抗血清可裂解来自所有人类慢性粒细胞白血病（CGL）患者以及部分急性粒单核细胞白血病（AMML）供者的白血病细胞。这些抗血清对急性髓细胞白血病（AML）、急性淋巴细胞白血病（ALL）、慢性淋巴细胞白血病（CLL）患者的细胞或正常供者的外周血淋巴细胞无细胞毒性。除了与CGL和AMML供者的细胞发生反应外，山羊抗梯度纯化FLV的抗血清还与AML患者和部分ALL供者的细胞发生反应。然而，该抗血清与CLL患者的细胞不发生反应。临床缓解期白血病患者外周血和骨髓白细胞与抗FLV及FLV gp71的抗血清不发生反应。吸收实验表明，CGL细胞上与抗FLV gp71抗血清发生反应的抗原也存在于正常人血小板和中性粒细胞上。类似的吸收研究表明，FLV抗血清检测到的AML细胞上的抗原不存在于正常白细胞和血小板上，且似乎与哺乳动物RNA肿瘤病毒的主要内部p30抗原有关。FLV抗原能够吸收检测人类白血病相关抗原的非人灵长类抗血清的细胞毒性反应，这显示了肿瘤病毒与人类白血病细胞膜抗原之间的另一种抗原关系。当用CGL细胞检测时，FLV和FLV gp71抗原能够吸收猴和黑猩猩抗人髓细胞白血病抗原血清的所有细胞毒性活性。这两种分析交叉反应性的方法表明，FLV gp71抗血清与人类CGL细胞的细胞毒性反应所检测到的抗原决定簇不同于FLV gp71上负责抑制猿猴抗血清与CGL细胞反应性的决定簇。由于山羊和兔抗FLV及FLV gp71的抗血清能够通过直接细胞毒性检测和吸收来区分AML和CGL细胞，它们可能是用于髓细胞白血病血清学诊断的有价值试剂。此外，由于处于临床缓解期的AML和CGL患者的外周血细胞血清学呈阴性，这些抗血清作为治疗辅助手段可能也很有价值。本报告中的数据表明，无论人类白血病发生的机制如何，CGL和AML患者的细胞都具有某些与FLV结构成分如p30和gp71发生交叉反应的膜抗原。
